Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?

被引：6
|
作者：
Fiorelli, Alfonso [1 ]
Vitiello, Fabiana [2 ]
Morgillo, Floriana [3 ]
Santagata, Mario [4 ]
Spuntarelli, Chiara [4 ]
Di Domenico, Marina [5 ]
Santini, Mario [1 ]
Bianco, Andrea [6 ]
机构：
[1] Univ Campania Luigi Vanvitelli, Thorac Surg Unity, Dept Translat Med Sci, Naples, Italy
[2] Hosp Vincenzo Monaldi, Dept Pneumol & Oncol, Naples, Italy
[3] Univ Campania Luigi Vanvitelli, Oncol Unit, Naples, Italy
[4] Univ Campania Luigi Vanvitelli, Maxillo & Orofacial Unit, Naples, Italy
[5] Univ Campania Luigi Vanvitelli, Gen Pathol Unit, Naples, Italy
[6] Univ Campania Luigi Vanvitelli, Pneumol Unity, Dept Translat Med Sci, Naples, Italy
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷
关键词：
D O I：
10.21037/tcr.2019.06.28
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S618 / S620
页数：3
相关论文
共 50 条
  • [1] PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC
    Jorgensen, Jan Trost
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
  • [2] PD-L1 Very High Expression Associated with Clinical Outcome of Pembrolizumab Monotherapy of Advanced NSCLC with PD-L1 TPS of 50% or Greater
    Itani, H.
    Nigi, A.
    Iwamoto, K.
    Ito, Y.
    Tanigawa, M.
    Kondo, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S662 - S663
  • [3] 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC
    Velcheti, Vamsidhar
    Rai, Pragya
    Kao, Yu-Han
    Chirovsky, Diana
    Nunes, Ana Tablante
    Liu, Stephen, V
    CLINICAL LUNG CANCER, 2024, 25 (06)
  • [4] Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression
    Kunimasa, Kei
    Nakamura, Harumi
    Nishino, Kazumi
    Nakatsuka, Shin-ichi
    Kumagai, Toru
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : E231 - E233
  • [5] Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.
    Piedra, A.
    Barba Joaquin, A.
    Mosquera Martinez, J.
    Fernandez Bruno, M.
    Cordeiro Gonzalez, P.
    Sullivan, I. G.
    Riudavets Melia, M.
    Aguado Sorolla, M.
    Gallardo Melo, P.
    Martin Cullell, B.
    Gavira, J.
    Tapia, J. C.
    Romano, A.
    Bosma, F.
    Sanchez Del Rio, S.
    Sanz Beltran, J.
    Molina Perez, M. A.
    Serra Lopez, J.
    Garcia Campelo, M. R.
    Majem Tarruella, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1053 - S1053
  • [6] Benchmarking the efficacy and safety of pembrolizumab plus chemotherapy to pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression
    Takumida, H.
    Horinouchi, H.
    Masuda, K.
    Shinno, Y.
    Okuma, Y.
    Yoshida, T.
    Goto, Y.
    Yamamoto, N.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S855 - S856
  • [7] Clinical significance of inter-assay discrepancy in PD-L1 expression evaluation for the efficacy of pembrolizumab in advanced NSCLC patients with high PD-L1 expression
    Miyakoshi, Jun
    Kashima, Jumpei
    Shirasawa, Masayuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Horinouchi, Hidehito
    Shiraishi, Kouya
    Kohno, Takashi
    Yamamoto, Noboru
    Yatabe, Yasushi
    Ohe, Yuichiro
    CANCER RESEARCH, 2024, 84 (06)
  • [8] Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801
    Shinobu Hosokawa
    Eiki Ichihara
    Daijiro Harada
    Shoichi Kuyama
    Koji Inoue
    Kenichi Gemba
    Hirohisa Ichikawa
    Yuka Kato
    Naohiro Oda
    Isao Oze
    Tomoki Tamura
    Toshiyuki Kozuki
    Takahiro Umeno
    Toshio Kubo
    Katsuyuki Hotta
    Akihiro Bessho
    Yoshinobu Maeda
    Katsuyuki Kiura
    International Journal of Clinical Oncology, 2022, 27 : 1139 - 1144
  • [9] Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801
    Hosokawa, Shinobu
    Ichihara, Eiki
    Harada, Daijiro
    Kuyama, Shoichi
    Inoue, Koji
    Gemba, Kenichi
    Ichikawa, Hirohisa
    Kato, Yuka
    Oda, Naohiro
    Oze, Isao
    Tamura, Tomoki
    Kozuki, Toshiyuki
    Umeno, Takahiro
    Kubo, Toshio
    Hotta, Katsuyuki
    Bessho, Akihiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1139 - 1144
  • [10] Real-world evaluation of pembrolizumab monotherapy for previously treated PD-L1 positive (TPS>1%) advanced NSCLC in France
    Perol, M.
    Quantin, X.
    Lena, H.
    Filleron, T.
    Chouaid, C.
    Valette, C. Audigier
    Kaderbhai, C.
    Chenuc, G.
    Santorelli, M.
    Bensimon, L.
    Burke, T.
    Simon, G.
    Martin, A-L.
    Debieuvre, D.
    Gervais, R.
    Schott, R.
    Carton, M.
    Courtinard, C.
    Girard, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S758 - S758
12345